Is Lamotrigine an Antidepressant?

Lamotrigine is not classified as an antidepressant, but it has a well-documented ability to prevent and treat depressive episodes, particularly in bipolar disorder. Originally developed as an antiseizure medication, it works by inhibiting sodium channels in the brain to reduce repetitive neuronal firing and the pathological release of glutamate, an excitatory neurotransmitter linked to mood regulation.¹ Its FDA approval covers epilepsy and the maintenance treatment of bipolar disorder, not depression per se, yet prescribers reach for it constantly when depression is the dominant problem in bipolar illness. The distinction between “antidepressant” and “mood stabilizer with antidepressant properties” matters more than it might seem, because that distinction shapes how and when the drug gets used.

Where the Antidepressant Evidence Is Strongest

Lamotrigine’s clearest antidepressant credentials come from bipolar maintenance studies. In an 18-month placebo-controlled trial comparing lamotrigine and lithium, lamotrigine was significantly better than placebo at delaying the return of depressive episodes, while lithium was not.² A Cochrane systematic review confirmed the pattern: lamotrigine outperformed placebo in suppressing depressive symptoms, reducing the rate of depressive recurrence, and lowering the need for additional medications over six months or more.³ A 2024 meta-analysis of maintenance trials found that patients on lamotrigine had about a 16% lower rate of relapse or recurrence than those on placebo.⁴

For acute bipolar depression, the picture is more modest but still positive. A 2025 meta-analysis of randomized controlled trials found a small but real advantage for lamotrigine monotherapy over placebo in the acute phase of bipolar depression.⁵ A large network meta-analysis in The Lancet Psychiatry placed lamotrigine among the treatments more effective than placebo for acute bipolar depression, though its effect size was at the lower end of the range, behind options like quetiapine and lurasidone.⁶ In plain terms: lamotrigine is a better preventer of bipolar depression than it is an acute rescue drug, but it does have some acute benefit.

How It Differs from Standard Antidepressants

Traditional antidepressants like SSRIs and SNRIs work primarily on serotonin or norepinephrine systems. Lamotrigine takes a fundamentally different path. By calming overactive sodium channels and reducing excess glutamate release, it dials down a different kind of neural overexcitement. Animal research has shown that chronic lamotrigine treatment raises levels of brain-derived neurotrophic factor (BDNF), a protein involved in the growth and survival of neurons, in the prefrontal cortex and hippocampus. Blocking BDNF signaling in those same animal models erased lamotrigine’s antidepressant-like effects, suggesting that BDNF plays a central role in how the drug lifts mood.⁷ A separate rat study confirmed that both short-term and long-term lamotrigine treatment increased BDNF and nerve growth factor in the prefrontal cortex and reduced immobility in behavioral tests commonly used to screen for antidepressant activity.⁸

This mechanistic difference matters clinically for one critical reason: conventional antidepressants carry a risk of flipping bipolar patients into mania. Lamotrigine does not. In a study of depressed bipolar patients, only about 5% of those taking lamotrigine switched into mania, a rate statistically indistinguishable from the roughly 5% seen with placebo. That gives prescribers something they rarely get in bipolar depression: a drug that treats the low without triggering the high.

Using Lamotrigine for Ordinary (Unipolar) Depression

If you have been prescribed lamotrigine for depression without a bipolar diagnosis, your doctor is using it off-label, typically as an add-on when first-line antidepressants have not worked. The evidence here is real but thinner and more geographically uneven. A meta-analysis pooling trials of lamotrigine augmentation in treatment-resistant unipolar depression found significant improvements in depression scores and response rates overall, though the positive signal came primarily from Chinese studies, while two non-Chinese studies did not reach statistical significance on their own.⁹

A small head-to-head trial comparing lamotrigine add-on therapy with lithium augmentation in 34 patients with treatment-resistant depression found comparable results between the two. About half the lamotrigine group responded to treatment, and the drug was well tolerated.¹⁰ That study was small and open-label, so it is best read as suggestive rather than conclusive. The honest summary for unipolar depression: lamotrigine is a reasonable option to try when standard antidepressants fail, but the evidence is not strong enough for it to be anyone’s first-line recommendation.

How Lamotrigine Compares with Lithium

Lithium is the classic mood stabilizer, and lamotrigine is sometimes framed as its mirror image. Lithium’s strength is preventing mania; lamotrigine’s is preventing depression. In the 18-month trial mentioned earlier, lithium significantly delayed manic episodes compared to placebo, while lamotrigine significantly delayed depressive episodes.¹¹ An open-label effectiveness study designed to mimic real clinical practice found that patients on lamotrigine trended toward fewer depressive relapses relative to lithium, while lithium trended toward fewer manic relapses, though neither difference reached statistical significance.¹² For bipolar II depression specifically, a single-blind study found the two drugs performed about equally well as monotherapy.¹³

So clinicians often choose between them based on which pole of the illness dominates. If a patient’s biggest problem is recurrent depression and mania is infrequent, lamotrigine is the more logical pick. If mania is the main threat, lithium generally takes priority. The two drugs are also sometimes combined.

The Slow Start-Up and Rash Risk

One of the biggest practical differences between lamotrigine and a standard antidepressant is the pace at which you can take it. SSRIs can typically be started at or near a therapeutic dose on day one. Lamotrigine requires a slow, weeks-long titration, usually beginning at 25 mg per day and creeping upward over five to seven weeks to a target of 100 to 200 mg. The reason for this cautious ramp-up is a potentially serious skin reaction.

Across a large systematic review of over 18,000 patients in randomized controlled trials, about 8% developed some kind of skin reaction on lamotrigine, though the vast majority of these rashes were benign and self-limiting. The incidence of the serious forms, Stevens-Johnson syndrome and toxic epidermal necrolysis, was around 0.04%.¹⁴ That is low in absolute terms, but Stevens-Johnson syndrome is dangerous enough that the risk drives the entire dosing strategy. Rashes severe enough to require hospitalization occurred in roughly 1 in 300 adults and 1 in 100 children in clinical trials, and the risk was clearly increased when the dose was ramped up too quickly or when valproate was taken at the same time.¹⁵ Research has confirmed that slower titration reduces rash risk.¹⁶ The pediatric rate is notably higher: serious rash affects about 8 in 1,000 children aged 2 to 16, versus about 3 in 1,000 adults.¹⁷

If you have been on lamotrigine and miss several days, the dose usually needs to be re-titrated from the beginning rather than simply resumed at the previous level. Any new rash that develops during the titration period should be reported to a prescriber immediately.

The Valproate Interaction

Of all lamotrigine’s drug interactions, the one with valproate (sold as Depakote and similar brands) is the most clinically important. Valproate dramatically slows the body’s ability to clear lamotrigine, roughly doubling its blood levels. Studies in healthy volunteers confirmed that valproate markedly increased lamotrigine’s half-life and decreased its clearance.¹⁸ Further work showed the degree of inhibition is largely independent of the valproate dose; even low doses of valproate meaningfully slow lamotrigine elimination, with the maximal theoretical reduction in lamotrigine clearance reaching about 65%.¹⁹ This is why people taking both drugs together use a much slower titration schedule and a lower final dose of lamotrigine: the body is clearing it at almost half the normal rate, and the higher resulting blood levels amplify the rash risk.

Hormonal Contraceptives and Fluctuating Levels

Estrogen-containing birth control pills speed up the liver enzyme that breaks down lamotrigine, doing roughly the opposite of what valproate does. A narrative review found that estrogen-containing contraceptives consistently and significantly reduce lamotrigine blood levels, introducing substantial variability both between individuals and within a single pill cycle.²⁰ In a series of seven cases, oral contraceptives lowered lamotrigine levels by an average of about 49%, with a range of 41 to 64%. Some of those patients experienced seizure recurrence after starting the pill, or adverse effects after stopping it as levels rebounded.²¹

Not all progestins in combined pills affect lamotrigine equally. A study in women with epilepsy found that lamotrigine levels dropped significantly during the active-pill phase with drospirenone and levonorgestrel-containing pills but not with gestodene-containing ones.²² For anyone on lamotrigine and a combined hormonal contraceptive, this interaction means mood stability can fluctuate with the pill cycle. Some prescribers adjust the lamotrigine dose during the active and placebo pill weeks, while others recommend progestin-only contraception or a non-hormonal method instead.

Weight and Metabolic Side Effects

This is one area where lamotrigine genuinely shines compared to most other mood stabilizers and antipsychotics. A network meta-analysis of metabolic effects across bipolar treatments found that lamotrigine ranked lowest for metabolic disruption overall, while olanzapine ranked highest.²³ A review of weight effects of psychotropic drugs classified lamotrigine’s weight-gain risk as low, alongside carbamazepine and oxcarbazepine, and in contrast to the high risk seen with lithium and valproate.²⁴ For people who have gained weight on other psychiatric medications, this is often a major reason clinicians consider switching to lamotrigine.

Cognitive Side Effects, or Lack Thereof

Many psychiatric medications come with cognitive dulling, and patients understandably worry about trading mood stability for mental fog. Lamotrigine performs well here, too. A study comparing it with carbamazepine in patients with newly diagnosed epilepsy found that the lamotrigine group performed significantly better on verbal fluency and cognitive flexibility tasks.²⁵ A head-to-head comparison with topiramate (well known for its cognitive side effects) found that overall cognitive performance was significantly better with lamotrigine, with clinically meaningful advantages on verbal fluency and processing speed tests.²⁶ These studies were in epilepsy patients, but the results are reassuring for psychiatric patients as well: lamotrigine appears to be one of the more cognitively friendly options in the mood-stabilizer toolkit.

Pregnancy Considerations

Lamotrigine is one of the most studied anti-seizure drugs in pregnancy, and the available data is relatively reassuring compared to alternatives like valproate, which has a well-established risk of birth defects and developmental delays. A large registry-based study found that the risk of oral clefts in lamotrigine-exposed babies was not significantly elevated, estimating the excess risk at less than 1 in every 550 exposed pregnancies.²⁷ A prospective comparative study of 218 lamotrigine-exposed pregnancies found that the rate of major birth defects was similar to unexposed pregnancies, with no cases of oral cleft.²⁸

A 2025 analysis was more cautious, finding a fetal malformation rate of about 4.5% in lamotrigine-exposed pregnancies versus about 3.3% in untreated ones. That difference was not statistically significant and was not related to dose, but the authors noted it does not necessarily rule out lamotrigine being a weak teratogen.²⁹ The practical takeaway: lamotrigine is among the safer options if mood stabilization is needed during pregnancy, but dose monitoring becomes especially important, since pregnancy itself alters lamotrigine metabolism and blood levels can drop substantially.

Off-Label Psychiatric Uses

Lamotrigine’s glutamate-dampening and mood-stabilizing properties have attracted interest for conditions beyond bipolar disorder and epilepsy. In borderline personality disorder, a comprehensive review found that lamotrigine showed promise in reducing emotional dysregulation, mood instability, and impulsivity, with a safety profile generally comparable to other treatments used for the condition.³⁰ The evidence base remains limited, but given that borderline personality disorder has few pharmacological treatments with strong support, lamotrigine fills a gap for some patients.

Depersonalization disorder, a condition characterized by persistent feelings of detachment from yourself or your surroundings, has also been studied. A retrospective study of 32 patients found that over half achieved a meaningful reduction in depersonalization symptoms when lamotrigine was added to their existing antidepressant regimen.³¹ Higher doses and more severe baseline symptoms correlated with better responses, though the study was retrospective and uncontrolled.

What Happens in Overdose

Lamotrigine is generally safe at therapeutic doses, but overdose can cause serious problems, particularly affecting the heart and brain. Because the drug works by blocking sodium channels, high concentrations can delay electrical conduction in the heart, leading to widened QRS complexes and other EKG abnormalities. In one case report, a patient’s cardiac conduction changes did not respond to the standard treatment of sodium bicarbonate but resolved with intravenous lipid emulsion, which has since been described as a potential rescue therapy for lamotrigine cardiac toxicity.³²

A systematic review of published overdose cases found that the most common life-threatening symptoms were seizures, coma, low blood pressure, and abnormal heart rhythms. Children appeared more susceptible to seizures at lower blood concentrations than adults. Among cases involving lamotrigine alone, two adult fatalities were reported, both at very high ingested doses. Sodium bicarbonate, the first-line treatment for sodium-channel-blocker toxicity, failed to help in nearly half the cases with heart conduction delays, though some of those subsequently improved with lipid therapy.³³ This is worth knowing not as a scare tactic but as context: lamotrigine requires the same careful storage and prescription monitoring as any other medication that can cause harm in overdose, and emergency physicians treating a lamotrigine overdose should be aware that standard sodium-channel rescue with bicarbonate may not be sufficient.